Beste apotheek van Nederland

Briganti A, Salonia A, Gallina A et al. Drug insight: Oral
phosphodiesterase type 5 inhibitors for erectile dysfunction.
Nature Clinical Practice Urology 2005;2(5):239-247.
Briganti A, Salonia A, Zanni G et al. Erectile dysfunction and
radical prostatectomy: An update. Eau Update Series
2004;2(2):84-92.
Brindis R G, Kloner R A. Sildenafil in patients with
cardiovascular disease. [Review] [33 refs]. Am J Cardiol
2003;92(9A):26M-36M.
Brixius K, Middeke M, Lichtenthal A et al. Nitric oxide, erectile
dysfunction and beta-blocker treatment (MR NOED study):
Benefit of nebivolol versus metoprolol in hypertensive men.
Clinical & Experimental Pharmacology & Physiology
2007;34(4):327-331.
Broderick G A, Allen G, McClure R D. Vacuum tumescence
devices: the role of papaverine in the selection of patients. Br J
Urol 1991;145(2):284-286.
Brooks D P, Giuliano F. Genitourinary diseases. Drug
Discovery Today: Therapeutic Strategies 2005;2(1):iii-iiv.
Brown J S, Wessells H, Chancellor M B et al. Urologic
complications of diabetes. Diabetes Care 2005;28(1):177-185.
Buchholz N P, Weuste R, Mattarelli G et al. Post-vasectomy
erectile dysfunction. J Psychosom Res 1994;38(7):759-762.
Buddeberg C, Bucher T, Hornung R. [Erectile dysfunction in
men in their second half of life]. Urologe 2005;Ausg. A.
44(9):1045-1046, 1048-51.
Buena F, Swerdloff R S, Steiner B S et al. Sexual function does
not change when serum testosterone levels are
pharmacologically varied within the normal male range. Fertility
& Sterility 1993;59(5):1118-1123.
Bukofzer S, Livesey N. Safety and tolerability of apomorphine
SL (Uprima). Int J Impot Res 2001;13(SUPPL. 3):S40-S44.
Burls A, Gold L, Clark W. Systematic review of randomised
controlled trials of sildenafil (Viagra) in the treatment of male
erectile dysfunction. Br J Gen.Pract. 2001;51(473):1004-1012.
Burnett A L. Efficacy of tadalafil for the treatment of erectile
dysfunction at 24 and 36 hours after dosing: A randomized
controlled trial: Editorial comment 2. Urology 2003;62(1):126
Burnett A L. Vasoactive pharmacotherapy to cure erectile
dysfunction: fact or fiction?. [Review] [45 refs]. Urology
2005;65(2):224-230.
Burnett A L. The impact of sildenafil on molecular science and
sexual health. Eur Urol 2004;46(1):9-14.
Burns-Cox N, Gingell C. The andropause: fact or fiction?.
[Review] [49 refs]. Postgrad Med J 1997;73(863):553-556.
Buvat J. Hyperprolactinemia and sexual function in
men: a short review. [Review] [26 refs]. Int J Impot
Res 2003;15(5):373-377.
Buvat J, Boujadoue G. Testosterone replacement
therapy in the ageing man. The Journal of Mens
Health & Gender 2005;2(4):396-399.
Calof O M, Singh A B, Lee M L et al. Adverse events
associated with testosterone replacement in middleaged
and older men: A meta-analysis of randomized,
placebo-controlled trials. Journals of Gerontology
Series A-Biological Sciences & Medical Sciences
2005;60(11):1451-1457.
Campbell M. Beneficial cardiovascular effects and
safety of sildenafil reported in trio of studies.
Cardiology Review 2001;18(6):27
Cappelleri J C, Siegel R L, Glasser D B et al.
Relationship between patient self-assessment of
erectile dysfunction and the sexual health inventory
for men. Clin Ther 2001;23(10):1707-1719.
Cara A M, Lopes-Martins R A B, Antunes E et al. The
role of histamine in human penile erection. Br J Urol
1995;75(2):220-224.
Carani C, Bancroft J, Granata A et al. Testosterone
and erectile function, nocturnal penile tumescence and
rigidity, and erectile response to visual erotic stimuli
in hypogonadal and eugonadal men.
Psychoneuroendocrinology 1992;17(6):647-654.
Carani C, Scuteri A, Marrama P et al. The effects of
testosterone administration and visual erotic stimuli on
nocturnal penile tumescence in normal men. Horm
Behav 1990;24(3):435-441.
Cardenas D D, Ditunno J, Graziani V et al. Phase 2
trial of sustained-release fampridine in chronic spinal
cord injury. Proc Annu Clin Spinal Cord Inj Conf
2007;45(2):158-168.
Carey M P, Johnson B T. Effectiveness of yohimbine
in the treatment of erectile disorder: four meta-analytic
integrations. Arch Sex Behav 1996;25(4):341-360.
Carey Michael P, Wincze John P, Meisler Andrew W.
Sexual dysfunction: Male erectile disorder. Barlow,
David H (Ed) 1993;(1993):534
Carosa E, Benvenga S, Trimarchi F et al. Sexual
inactivity results in reversible reduction of LH
bioavailability. Int J Impot Res 2002;14(2):93-99.
Carson C C. PNU-83757: a new agent for the
treatment of erectile dysfunction.[comment]. Curr
Urol Rep 2002;3(6):465-466.
D-60